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Pancreatic cancer is a challenging cancer with a high mortality rate and a 5-year 
survival rate between 2% to 9%. The role of biomarkers is crucial in cancer prognosis, 
diagnosis, and predicting the possible responses to a specific therapy. The Discovery and 
development of various types of biomarkers have been studied intensively in the hope of 
determining the best treatment approaches, better management, and possibly cure of this 
deadly cancer. However, metastasis, responsible for about 90% of the deaths from cancer, 
is still poorly understood. A few research that have investigated the expression of a 
particular biomarker or a panel of biomarkers in the primary and secondary (metastatic) 
tumor demonstrates that the expression of different biomarkers in the primary and 
secondary tumor sites is not necessarily the same, even though the primary and metastatic 
tumor cells are originated from the same organ. In this project, we aim to design a classifier 
to distinguish between primary and secondary tumor cells based on their uptake of different 
biomarkers, using immunofluorescence whole slide imaging. For this purpose, we first 
register consecutive images of the same slide together to be able to locate multiple 
biomarkers that belong to a cell and later we design our classifier based on vectors that 
show the presence or absence of multiple antibodies in addition to the amount of that 
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1.1. Pancreatic cancer 
 
Pancreatic cancer initiates in the pancreas, a body organ located behind the stomach 
and next to the small intestine, Fig 1. This organ, which consists of three parts: head, body, 
and tail, has two kinds of cells: endocrine cells and exocrine cells. Endocrine cells secrete 
hormones such as insulin to regulate blood sugar. Exocrine cells release enzymes to help 
with food digestion. The different kinds of pancreatic cancer are divided into two main 
groups; exocrine tumors and neuroendocrine tumors. 
Pancreatic Ductal Adenocarcinoma (PDAC), an exocrine tumor, is one of the most 
common types of pancreatic cancer that occurs in the pancreatic ducts. Due to the location 
of the pancreas in the belly, pancreatic tumors are not usually felt by pressing the belly. 
The symptoms appear when cancer has spread to other body organs, which explains why 
pancreatic cancer is rarely diagnosed at the stage when it could be cured [1]. 
Despite all advances in cancer treatment, this malignancy still remains one of the 
deadliest cancers. Its 5-year survival rate ranges from 2% to 9 % in the United States [2], 
and approximately 7% of all cancer deaths come from this type of cancer [3]. Although the 
main causes of this type of cancer are not yet identified, factors such as smoking, obesity, 







Fig 1. Location of the pancreas in the body (Image courtesy Mayo Clinic) 
 
 
Although this challenging cancer is not curable and has an abysmal survival rate, 
fast-paced cancer studies in recent years have deepened our understanding of the biology 
of pancreatic cancer which in turn has affected the management of this cancer in different 
aspects such as early detection, medical therapy, and drug development. According to the 
World Health Organization (WHO), a biomarker is defined as “any substance, structure, 
or process that can be measured in the body or its products and influence or predict the 
incidence of outcome or disease.”[4] . The discovery and development of minimally 





important steps for moving toward personalized medicine and avoid unnecessary 
treatments with the high cost and adverse side effects on the patients [5]. Also, different 
imaging modalities in combination with biomarkers have provided ample opportunities for 
improving cancer detection and treatment and have made designing patient-specific 
therapies for different types of cancer more feasible while the biomarker assessment 
indicates the presence of any disease, imaging techniques can facilitate this task. Also, they 
can be harnessed to locate the tumor and identify the aggressiveness of the tumor [6].Whole 
slide imaging is one of the most recent imaging modalities with novel technology, which 
has several clinical and non-clinical applications that can be used to test for the presence 
of any cancerous antibody. 
1.2. Problem statement and Organization of this Thesis 
 
The ultimate goal of this project from the outset was to develop an algorithm that 
would be able to classify pancreatic cancer cells into primary or metastatic (secondary) 
categories based on the differential uptake of antibodies as a tumor marker.  Sets of 
antibodies with fluorescent labels are applied to the tissue and imaged.  The tissue is 
washed between applications. Since a glass slide is manually located inside the tray of a 
whole slide image scanner, each rescan of the tissue results in an image with the tissue at 
a slightly different orientation and therefore different coordinates for collocated pixels, 
consequently, coordination of the points will change. This problem is resolved by 
registering the consecutive images of a slide together. In order to analyze the presence or 
absence of all antibodies in consecutive images of a tissue, prior to ascertaining which cells 
are taking up which antibodies, the different scans must be registered.  Once the scans are 





in addition to each antibody’s expression associated with the cell. Together, these form the 
components of a feature vector, all vectors create a big matrix which will be the input to 
machine learning algorithms developed for classifying the cells. In this research, after an 
introduction about pancreatic cancer in chapter one, we will give an overview of the 
problem and explain how we will be dealing with this problem. In chapter two, we will 
describe the digital pathology or whole slide imaging system, its applications, benefits, and 
drawbacks. Later we broadly talk about biomarkers and tumor environment in pancreatic 
cancer and explain how the use of biomarkers is important in the prognosis, diagnosis, and 
prediction of different therapeutic approaches in pancreatic cancer and how intensive 
research in this area is bringing hope for better management and even cure of this deadly 
disease.  
In chapter 3, we will be working with thumbnail brightfield and 
immunofluorescence images. First, we register two consecutive brightfield thumbnail 
images based on finding fiducial markers, and in the second part we will be registering 
immunofluorescence images of the tissue samples. 
In the evaluation of differences between normal and cancer cells - the details of 
which are outside the scope of this project - usually morphology differences are analyzed. 
Cancerous cells are different from normal cells in both shape and size. Figure 2 shows 
some of the morphological differences between normal and cancerous cells. These 
differences give the opportunity to design a classifier based on a single or a panel of 
features including area, axes lengths, eccentricity, perimeter, circularity, and other 
morphological characteristics. Most of the classifiers are designed based on normal versus 





the differences between primary tumor and metastatic tumor cells; The first type is a 
morphology-based classifier to analyze if primary tumor and metastatic tumor cells are 
distinguishable morphologically. Finally, the second type of the classifier is designed to 




Fig 2. Normal cells versus cancer cells morphological characteristics [7] 
 
 
The proposal of this project was based on immunohistochemical brightfield whole 





that we received. Those data sets were received sequentially over the course of this project. 
First, we found the fiducial markers inside the thumbnail images of a whole slide image 
and registered two thumbnail images together based on these markers. Later, we received 
two non-consecutive large brightfield whole slide images, and we started to work on those. 
Shortly after, we received several small size brightfield images in different proprietary 
formats and worked to change the format into .tiff or .jpeg to be able to process them. We 
experienced a loss of information while converting to .jpeg or .tiff, and this is unacceptable 
for the accuracy standards of pathology. Finally, we received immunofluorescence whole 
slide images in small sizes (1017 x 1920 pixels) of primary and metastatic tumors. Only 
for two patients did we have both primary and metastatic information. The images for the 
remaining patients are either primary or metastatic without any ground truth. The public 
datasets are mostly brightfield images of different types of cancer, and our aim was to 
classify pancreatic cancer cells based on either morphology characteristics or uptaking 
antibodies in immunofluorescence whole slide images. Besides, pancreatic cancer is 
difficult for pathologists because “acini are cut obliquely, making it difficult to discern 
their characteristics shape” [8], therefore images of other types of cancer are an insufficient 




















Before we start describing methods of registration of immunofluorescence whole 
slide imaging and apply them to see the results of the registration and to locate multiple 
biomarkers in chapter 3 and later classification of primary versus metastatic cancer cells in 
pancreatic cancer in chapter 4, we introduce the whole slide imaging system (WSI), the 
notion of biomarker and tumor microenvironment in this chapter. Also, based on reviewing 
the existing literature we provide the background behind these concepts, explain how tumor 
environment contributes in tumor progression and metastasis, discuss potential biological 
markers in pancreatic cancer and how they can be promising in prognosis, diagnosis or 
prediction of responses to different therapeutic approaches.  
 
 
The quality of the microscope was enhanced since 1850, which paved the way for 
the first pathology practices to start. Since that time, pathologists have been using the 
traditional microscope as the gold standard for the diagnosis of cancer and other diseases. 
Nevertheless, advances in digital imaging and image processing have opened a window to 
move from traditional microscopy to virtual microscopy [9]. Figure 3 presents the 






Fig 3. The evolution of pathology over time [10] 
 
Wetzel and Gilbertson developed the first high-resolution whole-slide imaging 
(WSI) system in 1999 [11]. In digital pathology, or Whole slide imaging, the glass slides 
are scanned by a high-resolution scanning device under brightfield or fluorescent 
conditions, and a high-resolution digital image of the entire microscope slide is created 
[12]. The total scan time of a glass slide is less than one minute, with a resolution 
comparable to seeing glass slides under a traditional microscope. Scanning can occur at 
different magnifications. However, 20X magnification is acceptable for routine image 
analysis. The digitization process includes scanning, storage, editing, and display. Each 
whole slide imaging system consists of these components: light source, slide stage, 
objective lenses, and a high-resolution camera [12]. In brightfield microscopy, which is the 
most common type of microscopy, the light passing by the specimen is collected by the 
objective lens beneath the specimen [13]. In fluorescent microscopy, specific structures in 
the sample are labeled with fluorescent dyes named fluorophores. Only a few things in the 
tissue sample are labeled with these fluorophores and therefore light up. This enables 
practitioners to only see and focus on particular structures or objects instead of everything 





Between brightfield and immunofluorescence microscopy, which are both 
molecular examinations of a microscope slide to detect specific proteins within the tissue, 
brightfield is the most popular and preferred method for cancer diagnosis by pathologists. 
However, there is an increasing demand for utilizing immunofluorescence in multiplex 
biomarker detection because it can detect more than one biomarker per slide. Its 
counterpart, brightfield microscopy, is performed to detect only a single biomarker per 
slide. This might disrupt the tissue since it is being dyed and washed out several times [15]. 
In addition to its ability to detect multiple biomarkers, one of the most important 
advantages of using fluorescence microscopy is that intensity is linear with the amount of 
proteins. However, since low abundance proteins have weak signals, it is hard sometimes 
to pull out these signals from underneath the bright signals [16]. Fig 4 represents a whole 
slide image sample.  
 In digital pathology all the information, including slides and data can be examined, 
managed, and shared in a digital environment. Whole Slide Imaging (WSI) increases the 
workflow efficiency, offers decision support tools, and creates a connected team 
environment that allows for the sharing of slides, team annotations, and markups remotely. 
Also, Whole Slide Imaging could lead to considerable enhancement in translational 
research and computer-aided diagnosis (CAD). Also, digitization gives the ability to 
measure multiple areas of interest, evaluate several different viewing angles, views with 
more accuracy, and gain new and better insights from analyzing a massive number of 
images. All of this makes training, remote consultation, and clinical review easier [17]. 
Despite all the benefits of WSI, the high cost of scanners along with the need for a 





issues, there is also the challenge of the rate of pathologists who are familiar with this 
technology being low at this point in time [18]. 
 
Fig 4. Omnyx whole slide imaging scanner and viewer [18] 
 
For the first time in 2017, the United States food and drug administration (FDA) 
approved the first commercial whole slide imaging (WSI) system, allowing the Philips 
IntelliSite Pathology Solution (PIPS) which reviews and interprets digital surgical 
pathology slides which have been prepared from biopsied tissue to enter the marketplace 
[19]. 
After the increased interest in the most recent imaging modality, whole slide 





Researchers and practitioners continue to wonder if whole slide imaging is as accurate as 
the optical microscopy that uses conventional glass slides. This led to a broad range of 
research related to clinical validation and standardization of this kind of imaging. 
In several studies about surgical pathology - the analysis of a removed tissue from 
a living patient during surgery for diagnosis and treatment plan - WSI and traditional light 
microscopy have been compared. These studies show that WSI is not inferior to light 
microscopy, with one important caveat: WSI should be used for diagnosis purposes only 
when the pathologists are formally trained on the equipment. WSI has also been compared 
to traditional glass slides in the realm of primary diagnosis in anatomic pathology.  It is 
likewise non-inferior to its long-established counterpart in this dimension either [20]. A 
meta-analysis, comprehensive literature search, among several publications from 2013 to 
2019, which in total examined 10410 histology samples, demonstrated that there was a 
98.3 % concordance between digital pathology (DP) and light microscopy (LM). 
Therefore, there is an equivalency between DP and LM in routine diagnosis. Although the 
discrepancies should be studied deeply before this emerging technology will take over 
permanently [21]. The College of American Pathologists states that each laboratory that 
works with whole slide systems, should conduct its own validation studies to be able to use 
digital pathology for diagnostic purposes [22]. 
 
 
Research in cancer biology shows that the progression of cancer is not solely related 
to changes in the tumor cells, as changes in the tumor microenvironment play a critical role 
in tumor development and progression [23]. There are multiple exchanges between 





initiation, development, and progression of cancers a comprehensive analysis of tumor 
microenvironment to understand how it affects tumor growth and metastasis is essential. 
its mutual are highly dependent on interactions between the cancerous and nonmalignant 
cells in the tumor microenvironment [24-25]. 
 
The concept of tumor microenvironment (TME) dates back to 1889 when Stephen 
Paget after examining the data of 735 women with breast cancer and noticed that metastasis 
did not happen by chance, in fact for cancer cells (the seed) to metastasize a favorable 
microenvironment  (the soil) is needed [26]. Tumor microenvironment is not only 
important in metastasis but also the dynamic interactions of cancer cells with cellular and 
acellular components of tumor microenvironment affects tumor growth and progression.  
 
Pancreatic cancer is one of the most dangerous types of cancers with a high 
mortality rate and a dismal prognosis. Most patients are diagnosed at the stage when the 
tumor is locally advanced or has metastasized to other organs and therefore is not 
resectable. The close incidence rate and mortality rate of this malignancy has fueled the 
research to look deeply beyond the cancer cells and to further investigate the tumor 
microenvironment and its vital role in cancer progression to find novel therapeutic 
approaches for the treatment of pancreatic cancer. 
 
The pancreatic cancer microenvironment is made up of cancer cells, tumor stromal 
cells, immune cells like macrophages and extracellular components. The components that 





tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSCs) and 
pancreatic stellate cells (PSC) [25],[27]. 
Recent studies show that the tumor microenvironment of pancreatic cancer, 
including cancer-associated fibroblasts such as stellate cells, extracellular matrix, different 
kinds of immune cells, and cytokines released by these cells, participates in the control of 
proliferation, invasion, and metastasis, chemoresistance and immunotherapy of pancreatic 
cancer by close interactions with cancer cells [27]; The dynamic interaction between tumor 
cells and their surrounding tissue favors the survival of the cancerous cells in such a way 
that the cancer cells divide and grow out of control following oncogenic mutations and 
therefore elude anti-tumor immunity, while the tumor environment of pancreatic cancer 
ductal adenocarcinoma can impact local immune response [25], [27].  
 
There are two major characteristics of the pancreatic cancer microenvironment: 
dense desmoplastic reaction which is referred to suffusive growth of condensed fibrous 
tissue around the tumor, existing in both primary and metastatic tumors and extensive 
immunosuppression; Dense fibrous tissue prevents the infiltration of immune cells in the 
tumor tissue, making the tumor tissue escape from the surveillance of the immune system. 
The desmoplasia builds a barrier around the tumor cells and therefore creates a 
hypoxic microenvironment in which prevents the proper formation of blood vessels and 
limits the exposure to chemotherapy and in consequence leads to poor immune cell 
infiltration. In such a hypoxic environment, the oxygen consumption is increased, and 
oxygen supply is compromised. Also, immunosuppressive molecules and cells by changing 





facilitates cancer cell proliferation, the evasion of immune surveillance via the direct 
inhibition of anti-tumor immunity or the induction of immunosuppressive cell proliferation 
and metastasis [28]–[32]. 
Such an environment with these characteristics makes pancreatic cancer resistant 
to different kinds of therapy such as chemotherapy, radiation therapy and immunotherapy 
and this, in turn, promotes metastasis [28] ,[33]. Therefore, novel approaches to understand 
how different components of the pancreatic cancer microenvironment contributes to cancer 
progression and metastasis provide better insight to develop more effective treatments. For 
instance, an important question to be investigated is whether the tumor microenvironment 
characteristics in primary organ differ from the secondary organ when the tumor is 
metastasized [31]. Up to date, several approaches and methods to treat pancreatic cancer 
have failed or had unsatisfactory results Immunotherapy has improved cancer treatment 
significantly in several malignancies; however, pancreatic cancer due to its unique complex 
microenvironment remains unresponsive to conventional immunotherapies. However, 
advances in several fields such as biology, genetic and immunology with emerging tools 
like immunophenotyping, fluorescence multiplex imaging will facilitate deep 
understanding of the tumor microenvironment and successful personalized therapies 
hopefully in the near future [30-31], [34]. 
 
The role of biomarkers is crucial in cancer screening, prognosis, diagnosis, and 
determining the best treatment approaches. Understanding the relationship between 
biomarkers and their clinical results is of great significance not only to increase treatment 





types of research have been performed since 1980 to examine the use of biomarkers in 
extremely important diseases such as cancer, and the FDA has continued to promote the 
use of biomarkers in clinical studies. However, biomarker-driven research has not been 
easy due to a variety of factors: the relatively low number of patients or healthy individuals 
that can be tested, the lack of assessment of the practicality of a proposed method, the 
selection of an early-stage group of patients, the healthy control groups, and the non-
specificity of molecular markers. 
Cancer biomarkers are classified into three groups; prognostic biomarkers that can 
provide valuable information to patients and assist clinicians in adjusting their treatment 
strategies according to the aggressiveness of the disease, diagnostic biomarkers that refers 
to those markers assisting with the early detection of cancer and potentially curable stage 
and predicting biomarkers that can help to predict how a patient might respond to treatment 
and how to select different treatment protocols based on a biological rationale in the very 
early stages of cancer that have the potential to improve patient survival rates [35]–[38]. 
 
In pancreatic cancer, one of the major challenges in biomarker development is 
obtaining tumor tissue samples of adequate quality for analysis. Initial diagnosis of this 
cancer is usually performed with fine needle aspiration (FNA), most commonly by 
endoscopic ultrasound, and therefore fair tissue procurement is difficult to obtain. Taking 
these biopsies is expensive, uncomfortable, and might lead to clinical complications.  
These data highlight the need for biomarkers that are highly specific and easily 
measurable by inexpensive sensitive techniques so that could improve the diagnosis and 





[38], In addition, due to the low incidence of pancreatic cancer in the population, 
stratification of the patients should be that accurate so that only those patients who truly 
need that, continue to undergo further examinations by invasive and expensive modalities. 
Therefore, minimally invasive modalities involving biomarkers and imaging techniques 
that would facilitate the early detection of pancreatic cancer are highly needed [39]- [40]. 
This complex biology and heterogeneity of cancer makes it hard to diagnose and 
treat effectively. Studies to develop novel potential biomarkers for diagnostic, predictive, 
and prognostic purposes have been an area of extensive research lately with the hope of 
finding effective management for this challenging cancer; however, none of them were 
used in clinical trials [41]-[42]. Serum carbohydrate antigen (CA) 19-9 was discovered in 
1979 [43], and it is the most validated diagnostic marker in pancreatic cancer with 
sensitivity and specificity of 79-81% and 82-90%, respectively, but it is not useful in 
screening due to its low sensitivity and specificity. Several other carbohydrate antigens 
such as CA 50, CA-125, etc., have also been investigated, but studies demonstrate that they 
are overall less sensitive than CA19-9 [44]. 
Among strategies to find predictive, prognostic, and diagnostic biomarkers for 
pancreatic cancer liquid-based biopsies to detect circulating tumor cells (CTCs), 
circulating free DNA (cfDNA), and extracellular vesicles (EVs) are promising markers for 
early detection and diagnosis of PC [45]. These biomarkers, along with methylated DNA 
and exosomes, can classify the patients with pancreatic cancer adenocarcinoma and predict 
their sensitivity to the therapeutic methods [39]. Several studies show that exosomes 
correlate with pancreatic cancer progression and metastasis, and due to the possibility of 





biomarkers in PC [46] Circular EV- based biomarkers are highly sensitive with high 
positive predictive value and low false positive value and offer an excellent opportunity 
for screening of individuals in pancreatic cancer [45]. Also, miRNA is another biomarker 
that has gained attention lately to be used as a marker for early detection of PC. For 
pancreatic cancer mass screening, affordable, convenient, and efficient testing with high 
sensitivity and specificity close to 100 % that can be utilized effectively for all the 
population is required [36]. 
 
 
Metastasis is responsible for the majority of cancer deaths; however, this phase of 
cancer has remained poorly understood. Most of the literature deals with differentiating 
between cancer versus normal situation in an organ [47]. A few studies have assessed the 
expression of particular biomarkers in primary versus metastatic tumors in select types of 
cancer. Stefanovic et al.[48] talk about how biomarkers change between primary and 
metastatic tumors, and how the accurate assessment of biomarker conversion between 
primary versus metastatic can minimize overtreatment for metastatic tumors. In [49] 
Bhullar et al show that some biomarkers are highly concordant between colorectal cancer 
and metastatic colorectal cancer, therefore a molecular examination of either a primary 
tumor or its corresponding metastatic site is enough for designing the individual treatment. 
Gomez-Roca and his colleagues [50] examined 49 patients to see if the expression of a 
group of biomarkers - epidermal growth factor receptor (EGFR), vascular endothelial 
growth factor receptor, Ki-67, and excision repair cross-complementing (ERCC1) - were 
concordant in non-small cell lung cancer and its metastatic site. They demonstrated that 





corresponding metastatic site in 33 percent of cases. In only 18 percent of the tested 
population, the expression of the biomarkers is the same in both primary and metastatic. 
Ansari et al. [51]examined 17 cases of primary PDAC and their lymph node metastases to 
study the expression of Mucin 4 (MUC4) antibody, which is a proposed role in pancreatic 
cancer progression during the cancer metastasis by comparing its expression in primary 
versus metastatic pancreatic ductal adenocarcinoma. They noticed that MUC4 was 
expressed in both primary and secondary tumor with concordance of 82 %.  
Therefore, based on the primary tumor, one cannot provide a suitable treatment 
plan, and based on what we see in the literature, much more research are necessary to 
evaluate the relationship between primary and metastatic biomarkers; their expression 
pattern, the amount of expression and the presence or absence of any antibody in both 






















In image processing, Image registration is the task of aligning two images that are 
taken from different viewpoints, different modalities or different time instances, involving 
the transform of one of the two images such that at the end they will be in one coordinate 
system. For this purpose, one image is used as the reference and the other one as the source 
image. A geometrical transformation which is a mathematical mapping from points in one 
image to the corresponding points in another image is calculated based on these two images 
to be applied to the source image so that these two images align with each other. In 
pathology, extracting information from different images of the same slide is done by 
pathologist looking at them one at the time and this is significantly time consuming. The 
assessment of expression of multiple biomarkers in a single view is possible only when the 
consecutive images of a slide are aligned [52].  
In this chapter, we will first register brightfield thumbnail whole slide images 
together using the location of fiducial markers which are artificially added landmarks to a 
slide. For this purpose, first, we need to detect the hashmarks in the images and later 
register the two images together. Later, we will register immunofluorescence whole slide 
images using corresponding features in both the reference image and the source image. 
Feature-based registration techniques extract naturally occurring features from the images 





Methods of image registration could be divided based on different criteria. One of 
the criteria is the nature of transformation [53]. Based on the Geometrical transformation 
the image registration is divided to 4 types as follows. In rigid image registration only 





3.1.  Registration using Fiducial Markers  
Since a glass slide is manually located inside the tray of a whole slide image 
scanner, each scan might result in an image with a slightly different [0 0] coordination, 
consequently coordination of the points will change and this problem will be resolved by 
registering the consecutive images of a slide together.   
A landmark is a recognizable feature that can be found in an image and can be used 
to match two images in the thumbnail images, fiducial markers are suitable choices to be 
used in image registration. For this purpose, first these markers should be detected and 
segmented in both images automatically. Figure 5 shows a sample of the thumbnail 
immunohistochemistry image that we use for detecting hash marks. As are seen the hash 






Figure 5. Thumbnail immunohistochemistry image sample 
The first method to detect fiducial markers starts with dividing the true color (RGB) 
thumbnail image to two halves and only the top half is kept for object detection purposes, 
because in this image the only thing that is needed for object detection and segmentation 
is the hash mark(s) signs. Then the top half RGB image is converted to grayscale and then 
to binary simply using Otsu thresholding method (Figure 5). As it can be observed, the 
white objects in the background are easily discernable, so these objects are labeled and then 
the properties of objects such as area, perimeter and etc. are calculated, then the boundaries 
for target objects(blobs) are plotted. This also gives the coordinates of the hashmarks. 
Finally, the detected hashmarks are imaged. Fig 6-9 and 10-11 present the results of the 






Figure 6. Binary image of the thumbnail image 
 
Figure 7. Coordinates of Hash mark number 1 
 













   










Figure 11. First and second hash mark boundaries and images 
 
The second method for finding hash marks inside of the rotated image is template 
matching. Template matching is a measure of similarity between a predefined template and 
a reference image. Templates are usually used to identify small simple objects in a bigger 
image. There are several methods for template matching such as Naive template matching, 
image correlation matching and sum of absolute differences [54]. In image correlation 
matching, the position of the given pattern is determined by a pixel wise comparison of the 
image with the template that contains the desired pattern. To calculate this comparison, 
normalized cross correlation is a reasonable choice. Normalized cross correlation (NCC) 





between -1 and 1 which 1 means the two images are identical and -1 means one image 
negates the other image and finally 0 means the two images are not correlated at all. In this 
method the maximum correlation coefficient is at the starting point of the template. Figure 












Figure 12. Rotated image(left) and the template (right) 
 
After the hashmarks are detected, then the coordinates of their corresponding 
corners are used to calculate the transform matrix and then to align the rotated 





image, the rotated thumbnail image and the rotated image registered to the original image 
respectively. 
 




























3.2. Image registration in WSI immunofluorescence images 
 
We previously described a method for registration of two thumbnail whole slide 
images using the coordination of the artificial landmarks.  However, a thumbnail image is 
a low-resolution image that gives only an overview of the high-resolution image. What we 
have, is a set of immunofluorescence images that need to be registered. Therefore, we 
developed automatic feature-based registration techniques which extract naturally 
occurring features from the images rather than rely on artificially created features.   
Analysis of the sequentially scanned whole slide images showed that the 
differences between slides did not include non-rigid deformation from one slide to the 
other. The differences between sequential images involved changes in intensity, rigid 
translation, and possibly rotation. Therefore, we developed schemes based on intensity, 
and on features extracted from the images. The result of intensity-based registration is 







Figure 16.  Intensity based registration result 
 







To be able to implement feature-based registration, first the features of interest 
(lines, points, ...) need to be extracted. Even though there are no perfectly circular shapes 
in the whole slide images, by applying the Hough Transform and limiting the radius of the 
circles we can identify roughly circular regions of the images which can be used to generate 
features for the registration process.  An example is shown in Figure 18 where the circular 
regions identified are shown as green circles. The centers of these circles were then used 




Fig.18 Hough Transform result 
 
The second method used for extracting key points to be used for feature-based 
registration made use of the regionprops algorithm which finds the centroids and areas of 












Figure 19.  Binarized Image  
 
The binarized image was processed using morphological operations of dilation and 
erosion.  The result is shown in Figure 20. The process results in the filling of “holes” in 
the image and filtering out some of the noise, resulting in isolated connected regions. 
 
 












If we now take an inverse of this processed image as shown in Figure 21, and then 
take the intersection of the inverted image and the original binarized image we obtain the 
image shown in Figure 22 that contains only the connected components (blobs) generated 
by the processing operation.   
 
 
Figure 22. Intersection of the inverse of the morphologically processed image from Figure 21 and the 








The centroids and areas of the connected components are found, and the three 
connected components with the largest areas are selected.  The centroids of these areas, 
shown by crosses in Figure 23 are used as features for constructing the affine matrix which 
is used for registering the images. 
 
Figure 23. Extracted points for Feature based Image registration are marked 
 
 
After the registration was completed, color thresholding was used to separate out 
the regions in the image that had taken up the different antibodies.  Recall that the 
antibodies fluoresce at different colors.  An example of an image with two different 
antibodies is shown in Figure 24. We can view each colored region as a cell or a set of cells 












Figure 24.  Example of an image with fluorescent labels green and red for two different antibodies. 
 
The following image shows the results of the color thresholding algorithm to obtain 













Each location which takes up a particular antibody is treated as an object and 
statistics for each object are collected for further analysis.   The statistics include the 
centroid of the objects, their major axis length, minor axis length, the area of every object, 
which is simply number of pixels for that object, and the perimeter of the object. A sample 















Table 1. A part of the calculated statistics for the green dots after applying the color thresholding algorithm 
 
Area Centroid(x) Centroid(y) Major Axis Length Minor Axis Length Perimeter 
25 563.44 308.92 6.908159097 4.773259323 15.341 
9 593 617 3.464101615 3.464101615 7.476 
15 597.6 664.6 4.760952286 4.188874153 10.751 
16 599.5 178 5.977883203 3.596050484 11.884 
18 601.666667 84.8333333 5.777885617 4.210362088 12.62 
12 619.5 422 4.618802154 3.464101615 9.436 
59 624.79661 484.254237 11.82523465 7.344929342 30.318 
21 655.571429 40.7142857 6.595402825 4.261516809 13.935 
147 665.959184 800.843537 14.75115672 13.07430351 43.253 
81 676.753086 144.037037 16.18902405 7.008253874 36.769 
99 677.121212 480.575758 12.34046587 10.38219809 33.147 
65 676.784615 533.076923 10.16041851 8.579686703 27.151 
55 678.054545 307.745455 9.641168609 7.530137069 24.314 
18 692 423.5 8 3.464101615 15.622 
131 696.992366 735.496183 15.35785436 11.50872129 42.955 
9 696 415 3.464101615 3.464101615 7.476 
9 697 426 3.464101615 3.464101615 7.476 
26 723.615385 7.19230769 7.889735877 4.393894448 16.54 
177 731.768362 600.237288 18.2798396 12.85635299 49.414 
23 748.869565 254.695652 8.061365453 3.902710368 15.895 
12 751.5 240 4.618802154 3.464101615 9.436 
78 760.051282 132.974359 12.78769674 8.146835774 30.583 
93 784.021505 396.516129 13.57905079 9.05811407 34.048 
85 824.576471 448.505882 12.73504546 8.791204916 32.667 
65 824.676923 513.907692 11.78267174 7.232278057 27.589 
120 832.766667 280.666667 16.35715314 9.53212038 39.027 
55 842.490909 179.509091 10.71159917 7.555746268 27.407 
77 846.506494 553.181818 15.70405159 7.41622206 38.737 
73 853.945205 73.1643836 10.95886725 8.733915833 28.35 
47 853.93617 473.702128 9.935543994 7.061943978 25.356 
133 858.984962 745.210526 15.88983429 10.82156048 39.862 
30 859 626.5 6.92820323 5.773502692 17.276 
83 869.650602 620.313253 10.89124318 10.04298462 31.236 
81 872.17284 657.271605 11.52393507 9.203321707 30.285 
40 896 168.575 9.725854469 5.584301345 21.709 
98 924.479592 363.091837 13.83665372 9.234508886 34.164 
31 923.580645 609.612903 9.587529376 5.27800052 21.593 
23 924.391304 321.565217 6.766533631 4.502862906 14.671 
29 928 120.551724 10.24975469 4.174740493 20.212 
159 932.201258 907.138365 21.86372059 12.42707264 66.31 





Speed Up Robust Features (SURF) is another approach in finding and matching 
features that are locally distinct points in an image to register WSI immunofluorescence 
images. The original algorithm used for key point detection is called SIFT (Scale Invariant 
Feature Transform). SURF is mainly inspired by SIFT but is several times faster than SIFT. 
One of the most critical advantages of SIFT features is that they are not affected by the 
scale or the orientation of the image. In SIFT algorithm, first, in order to reduce the noise, 
the image is blurred using Gaussian Blurring methods. By applying Gaussian Blur, minor 
details are removed from the image, and only information such as the shape and edges are 
remained. Then several scales of the original image are generated and later are blurred by 
Gaussian blur. In the next step Difference of Gaussian (DoG) is calculated such that one 
blurred image of the original image is subtracted from another less blurred version of the 
original image. In the next step, the key points are localized; the local maxima and minima 
are found, and later low contrast key points are removed. In order to find local maxima and 
minima, every pixel in the image is compared with its neighboring pixels and is selected 
as a key point if its value is the highest or the lowest among its neighbors. Now that the 
potential key points haveDesktopDe been specified, a final check is essential to choose the 
best key points; low contrast key points or those close to the edges are eliminated at this 
point. Now that the robust key points have been selected, an orientation value to each key 
point should be assigned so that the key point would be rotation invariant. For this purpose, 
the gradients in x and y directions and later magnitude and orientation for each pixel are 
calculated. 
In the next step, for each key point, a histogram of the magnitude and orientation 





would be the orientation of that key point. Finally, in the last step, using the neighboring 
pixels, their orientations, and magnitude, for each key point, a descriptor which is the 
representation of that specific point and contains the most important information about that 
key point, is generated [56]-[57]. In order to register two or more images based on SURF 
algorithm, first using SURF, features are extracted in both the reference and the source 
images. Then, the transformation matrix between the two images is calculated, and finally, 
the source image is registered to the reference image. Figures 26-30 show the original 















Figure 27. Dapi 2 
 
 





















In this chapter, we first registered two thumbnail images together based on fiducial 
markers we detected, using template matching and other methods. Later, we registered 
immunofluorescence whole slide images together using features in these images. For this 
purpose, we extracted naturally occurring features in the reference and the source images 
and then calculated the transformation to register the images together. The registration 
compensates for moving the tissue slide inside the scanner and brings all the consecutive 
images of each slide to the same coordinate system. In the next chapter, we will locate 
multiple biomarkers (antibodies) for each cell and using the antibody vectors, we will 
design our classifier to investigate the difference between primary and metastatic 
















Clustering and Classification 
 
Unsupervised learning is a kind of learning that looks for a pattern in the dataset 
with unlabeled data points. Clustering, which is one method of unsupervised learning, is 
the grouping of data points into subgroups that share similar properties. This method is a 
popular technique for statistical data analysis [58]. 
We deal with millions of pixels in only one sub image of a whole slide image. In 
order to be able to apply machine learning supervised classification methods on the dataset, 
unsupervised clustering methods could be an effective way to gain a general overview of 
the dataset and see how many different classes there are in the dataset. 
 In this chapter, first using unsupervised clustering methods such as Vector 
Quantization (VQ) and Principal Component Analysis (PCA), we investigate whether we 
could cluster the cells into two different groups. This can provide insight about the data we 
aim to classify ultimately. Later, we design two different classifiers based on 
morphological features and antibody uptake, using Support Vector Machine (SVM) to 










4.1.  Vector Quantization 
To see if we could cluster cells into two categories with different characteristics, 
we implemented one of the unsupervised clustering methods, LBG Vector Quantization 
algorithm, on every patient in the dataset.  
The preprocessing steps to prepare the images for both clustering methods, 
including converting the images to binary, are described in the classification methods 
section in detail. After completing the preprocessing steps, all the images are in binary 
format, therefore the value of each pixel is either zero or one. 
 
4.1.1.  First Method Pixel-Based Vector Quantization 
 
For the first method of pixel-based vector quantization, we started from the first 
pixel in the first image. Note that the number of primary images is 26 for 26 different 
antibodies, and the number of metastatic images is 26 for 26 different metastatic antibodies. 
Each pixel has a coordinate of [x y z], the x and y are length and width coordinates of the 
pixel in the image and z shows which among the 26 images this pixel is located in. For 
instance, [150 1103 24] indicates that the pixel is in [150 1103] coordinate in the 24th 
image. Starting from the first pixel in the first image, its value is either 0 or 1, which 
demonstrates whether or not that specific antibody exists in the respective pixel. The 
process continues onto the first pixel in the second image, coding it either 0 or 1, this goes 
on until the 26rd image. So, for every pixel with an [x y] coordinate, there is now a vector 





example could be [1 1 1 0 0 1 1 1 1 0 1 0 0 0 1 1 0 0 1 1 0 0 1]. After preparing all the 
primary images of a patient for VQ and completing the steps in order to have the primary 
vectors of that patient, a need for the [x y] coordinates of each pixel was determined. , It 
was possible at that juncture just to add the coordinates of each vector to the end of that 
vector and make a matrix vector. Finally, all of these vectors were placed in a long matrix. 
 
At this point, we implemented the Linde-Buzo-Gray (LBG) algorithm, which was 
introduced by Yoseph Linde, Andrés Buzo and Robert M. Gray in 1980 as a vector 
quantization algorithm. This method works quite similar to k-means clustering method, the 
only difference being that the k-means algorithm works with points in each step but in 
vector quantization it works with accumulated vectors in every step.  
For this purpose, LBG vector quantization algorithm was implemented in 
MATLAB. Additionally, the Python VQ built-in function was used to examine the 
accuracy of this implemented VQ program. It was observed that both programs' results are 
close to the same, but the Python VQ built-in function is faster than MATLAB. 
All these vectors summed together and would be referred to as a centroid. y0 equals 
this centroid, and y1 equals centroid plus another random vector. Considering that there 
are two vectors, y0 and y1. The next steps were making up a matrix, going to each location, 
taking the distance from y0, finding the ones that are closer to y0, and color-coding them 
blue for proximity to y0 and red for proximity to y1. Then all points that belong to y0 were 
averaged. This will be the new y0, then going to each location and taking the distance from 
y0 and find the ones that are closer to new y0 again, the same process was replicated for 





This VQ process was performed for all primary and metastatic directories. Figure 
31 shows that by using an unsupervised clustering method such as vector quantization, no 
specific pattern that shows any difference between two or more groups of cells was 
discernible. In the next section, we unpack the second approach to vector quantization that 
we attempted to see if the cells could be clustered unsupervised. 
 
 




4.1.2.  Second Method Pixel-Based Vector Quantization 
 
Preprocessing steps for this part are the same as what had been done in the last part 
termed first model pixel-based vector quantization. This time, in each image directory, one 
of the nuclei images is considered as the reference image. The antibody images which are, 





image named sum image. In the reference nuclei image, different nuclei are labeled as 
different objects. Due to their nature, cancerous cells do not have similar organized shapes, 
and which has a probable effect on the number of objects and the labeling process.  
 
Starting from the first pixel in sum image, if the pixel value is greater than or equal 
to one, then an area equal to 50 by 50 pixels around that pixel but in the nuclei reference 
image is searched in order to find nuclei and calculate the distance from the pixel in the 
sum image to the found nuclei. The distances from the [x y] coordinates of that pixel to 
each nucleus in that square are calculated, and the nucleus with the closest distance to that 
particular pixel is found. In a matrix all non-zero pixels in sum image are associated with 
a number that is the closest nucleus to that pixel. After this, the vectors associated to each 
pixel in sum image, will be generated. The length of this vector equals to the number of 
antibodies in the dataset; each element of this vector is either one or zero which shows the 
presence or absence of each antibody in that specific pixel respectively. Later all these 
vectors are concatenated in a long matrix and then all zero vectors are eliminated. After 
clustering the pixels using vector quantization, all pixels in the same cluster are color 
coding with the same color and different clusters are color coding with different colors. 
Figure 32 shows the result for this quantization method. As it can be observed from the 







Figure 32. Second model Pixel-based clustering using vector quantization 
 
 
4.1.3.  Object-Based Vector Quantization 
 
After the preprocessing steps, this time instead of investigating pixels for the 
absence or presence of antibodies, we studied the cells. To see which antibodies were 
associated with each cell, we found the center of each cell, then defined a vicinity of 50 
pixels around the center and checked this circle around the center of every cell to see which 
antibodies existed in this circle. We then defined a vector for each cell and for each 
antibody that exists in the cell’s neighborhood, with the related element in the vector as 1 
and the absence of each antibody as 0. We perform these steps for both primary and 
metastatic antibodies of a patient, and subsequently perform vector quantization for each 
one separately. The results are shown in Fig 33 to 40. It can be seen that there is not a 








































Figure 39. Object-based 2 clusters VQ for Liver Metastasis Patient 57 
 








4.2.  PCA (Principal Component Analysis) 
 
PCA or Principal Component Analysis is a technique to reduce the dimensionality 
of high-dimensional data sets. In fact, PCA projects input data onto a lower-dimensional 
subspace that still contains most of the information in the large set. It reduces the number 
of columns while preserving as much information as it can. In PCA, the axes are ranked in 
order of importance, with differences along the first principal component axis. The first 
principal component gives the maximum variance, and each succeeding component 
accounts for as much of the remaining variability as possible [61]. 
 
In this project, each variable belongs to a particular antibody, making it a 26 
dimensions dataset. in order to look for any insight into the data, PCA is implemented to 
make undertaking analysis a reasonable task.  
Prior to applying PCA, the data had to be prepared first. The images were converted 
to binaries, the different objects in the Dapi image were then labeled. The centroid of every 
object was calculated. A surrounding window around the centroid of each object was 
defined. Then in each antibody image, 26 in total, the coordinates of each object were 
located, and the surrounding window was applied and searched for that particular antibody. 
For each object, a vector was specified in which the presence of each antibody appeared as 
1 and the absence of that antibody appeared as zero. Once all the vectors were calculated 
for primary images of a patient, then all these steps were repeated for the metastatic images 
of that particular patient. Next, all the primary vectors followed by metastatic vectors were 
put in a long matrix. Finally, Principal component analysis was implemented in MATLAB. 





other patient cases, either primary or metastasis data exists in the dataset, but not both. 
Therefore, in order to attempt PCA for other patients, primary data of one patient 
concatenated to a metastasis data of another patient. Figures 41 to 43 show the result for a 




















Figure 43. PCA result for Primary data of patients 116 and 86, PCs 1 and 3 
 
 
As it can be noticed from the results, in cases when the data is both primary or both 
metastatic but from different patients, PCA could not cluster the data to two different 
groups. However, when the dataset is primary-metastasis data from one patient, PCA has 
clustered the data to almost two different clusters. Nevertheless, the results overlap in some 
cases and this makes them not very reliable. Most of the variance is explained by PCs 1 










4.3.  Classification Methods 
In a classification problem which is a supervised method, a dataset is divided into 
two classes for a binary classification or more for a multi-class classification, based on 
specific features. Features are properties or characteristics of the data that are the same in 
each class or sub population of a dataset [62]-[63]. Selecting proper features are extremely 
important as they can reduce the dimensionality of the data, exclude present attributes in 
the data and also help the classifier to make good predictions. Using a support vector 
machine, we designed three approaches for classification to see if it were possible to 
classify cells of a pancreatic cancer tissue into two classes of primary or metastasis using 
immunofluorescence whole slide images of pancreatic tumors. 
4.3.1.  Support Vector Machine 
Support vector machine (SVM) is a supervised machine learning method that 
originally debuted in the 1990’s in the work of Vapnik and Chervonenkis. First, it was only 
for linear classifying; however, later in 1992, Vapnik, Boser and Guyon suggested a way 
to a non-linear classifier [64]. SVM is among the fastest classifiers which can be used in 
two forms of linear and nonlinear. In the linear form, the classifier is able to divide the data 
into two categories by a line, while in the non-linear form, the dataset cannot be separated 
by a line and therefore other kinds of kernels such as Radial Basis Function (RBF) or 
SIGMOID function are used. Linear SVM uses a hyperplane to divide the data into two 
classes. This hyperplane is found such that to maximize the distance between the support 
vectors which are the closest points to the hyperplane. Figure 44 represents the linear SVM 





linear SVM works by mapping the dataset to a higher dimensional space where the data is 
separable. Figure 45 [66]. 
 



















4.3.2.  Dataset for the classification 
Immunofluorescence whole slide images of both primary tumor (pancreas tumor) 
and secondary tumor (either lung or liver) stained with different antibodies for patient 80 
and 105 exist. For other patients, the information of either the primary tumor or the 
secondary one exists. The dataset is very small, as the public datasets of cancers are mostly 
brightfield microscopic images and the number of whole slide images are very limited and 




4.3.3.  Preparing the dataset for the classification 
 
In order to prepare the images for two methods of classification in this project, i.e. 
cell morphology classification and antibody uptake classification sub-method 1, we needed 
to convert the color RGB images to binary. There are several methods for performing the 
binarization, however, not all of them give acceptable results. In this project we tried 
different methods for binarization such as OTSU Global thresholding, which is applied to 
all pixels in an image and it is based on the histogram of the gray scale version of that 
particular image [67]. If g(x,y) is the binarized image of f(x,y), the relation between g and 
f is an equation (1). The other method for binarization is adaptive or local thresholding,  
(1) 
in which different thresholds are calculated for smaller parts of an image. With 





the best results were obtained by using the watershed segmentation algorithm. The idea of 
Watershed segmentation which is a region-based approach comes from geography in which 
a piece of land is divided into several small parts when it is flooded by rain. The watersheds 
are in fact the lines that divide the land into several smaller parts. The original algorithm 
of watershed segmentation was proposed by Digabel and Lantu´ejoul and improved by 
Beucher and Lantu´ejoul [68]. The images are converted to binary using watershed 
segmentation and the result for one image is presented in figure 47. 
 
 






Figure 47. (Watershed Segmentation) for separating the cells (Patient 80 Primary Dapi) 
 
The images are now preprocessed. Altogether, there are 26 antibodies in the 
different images of primary and metastatic tumors. The list of antibodies are as follows:  
Bdac1, ccr3, cd103, cd11b, cd141, cd163, cd19, cd31, cd4, cd54ra, cd56, cd621, 
cd8, epcam, foxp3, gfap, gzmb, il10, il17, ki67, lox1, mct, mpo, muc1, prg2, sma 
For shaping the classification problem and solving that, two types of features are 
extracted from the immunofluorescence whole slide images of pancreatic cancer of the 
patients in the dataset. The first type of features is based on the uptake of each cell of 
different antibodies in the primary and metastatic tumors. The second type of features is 
based on morphology of the cells including area, perimeter, etc. The three methods of 
classifying the cells are presented in the following sections. 






4.4.1. Classification based on antibody uptake in binary images  
In this method, after converting the RGB images of the cells (dapi) and the 
antibodies to binary, with each antibody in a different fluorescent image--, we found the 
center of each cell and defined a vicinity of 50 pixels around the center to check this circle 
around the center of every cell to see which antibodies exist in this circle. Then we define 
a vector for each cell. For each antibody that exists in the cell’s neighborhood, the related 
element in the vector was given a 1; while in the absence of each antibody the element in 
the vector would be given a 0. These steps were performed for both primary and metastatic 
antibodies of all patients. Therefore, for each cell there will be a vector of 26 elements 
which these elements would be either zero or one. In the end, there will be a matrix with 
all primary tumor vectors followed by all metastatic tumor vectors.  
The primary cells are labeled as class 1 (C1) and the metastatic tumor cells are 
labeled as class 2 (C2). This long matrix would be fed to SVM. An example of the data 




























0 1 1 … 0 0 1 1 C1 
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1 1 1 … 1 0 0 0 C2 
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4.4.2. Classification based on antibody uptake in grayscale images  
In this method, only the images of the cells (dapi) are binarized. The antibody 
images are converted to grayscale images and then the intensities are normalized. When 





amount of the intensity of the antibody is put in the related element in the antibody vector 
instead of just a numerical one. So, for each cell, there will be a vector of 26 elements. At 
the end, there would be a matrix with all vectors of primary tumor antibodies followed by 
all vectors of metastatic tumor antibodies. The primary cells are labeled as class 1 (C1) and 
the metastatic tumor cells are labeled as class 2 (C2). This file is fed to SVM. An example 
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Object 3 0.01 0.003 0 … 0 0 0.005 C1 
...    …    C1 
Object 
1350 
0.045 0.0005 0.0032  0 0 0.033 C1 
Object 
1351 












…   Antibody2
6 
 
Object 1 0.022 0.0014 0.013 … 0 0 0.0067 C2 
Object 2 0.0013 0.044 0.065 … 0 0 0.0018 C2 
Object 3 0.0019 0 0.0061 … 0 0 0.009 C2 
…        C2 
Object 
1795 
0 0.006 0.018 … 0 0 0.0444 C2 
Object 
1796 
0.0012 0 0 … 0 0 0.0017 C2 











4.4.3. Classification based on Morphological features  
The second type of features is based on morphology of the cells. Morphological 
image processing are non-linear operations related to the shapes of objects in the images. 
The purpose of this part is to investigate if based on the morphology of the cells the 
classifier could differentiate between primary and metastatic tumor cells. An example of 
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Object 2 32 25.67 0.8421 … … 0.0
6 
0.9409 C1 
Object 3 … … … … … … … C1 
...    …    C1 
Object 
1350 
… … …  … … … C1 
Object 
1351 






 Area Perimeter Solidity …   Eccentricit
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Object 1 20 14.6 0.73 … … … 0.86 C2 
Object 2 8 13.72 0.99 … … … 1 C2 
Object 3 … … … … … … … C2 
…        C2 
Object 
1795 
… … … … … … … C2 
Object 
1796 
18 14.2 0.89 … … … 1 C2 








4.5. Results of the Classification  
4.5.1. Classification- Antibody uptake in binary images 
In this case, the highest accuracy reached was 82%. The classifier was trained with 
the primary and metastatic information of a patient and then tested with the information of 
another patient. In this method, the antibody vectors that have been generated for primary 
and metastatic tumor cells specify the information about presence or absence of the 
antibodies and inform whether or not they belong to the cell.  In fact, metastatic tumor cells 
are just primary tumor cells that immigrate through the blood or lymph systems to other 
places in the body. There is no typological difference in between primary tumor cells and 
metastatic tumor cells [69] only a differing amount of protein expression in some cases.  
Therefore, putting one for the presence of the antibody in the vicinity of the cell 
and putting zero for the absence of the antibody does not clarify if the protein expression 
of a specific antibody is different for primary versus secondary tumor cells. 
 
In this method, the classifier classified the cells(objects) mostly correctly when the 
borders of the cells were clearly specified, and the cells were separate. Therefore, this 
classifier works under the circumstance of clear borders for nuclei. Figure 48 to 50 show 
the results for metastatic tumor of patients 86, 105 and 8, respectively. The blue objects are 






Figure 48. Metastatic tumor patient 86, blue cells have been classified correctly and red cells have been 
classified wrongly 
 













4.5.2. Classification-Morphological features 
 
In this model, morphological features of the cells were extracted to be used in the 
SVM classifier. Our desire was to see if primary and secondary tumor cells were different 
in shape. The features that are used here are as follows: 
Area: Actual number of pixels in the object. 
Major Axis Length and Minor Axis Length: Length of the major axis and minor 
axis of the ellipse, respectively. 
Eccentricity: Eccentricity which its value is between zero and one is the measure 





Solidity: area of an object divided by the area of its convex hull. 
Perimeter: Distance around the boundary of an object. 
Elongation: Elongation is the ratio between the length and width of the smallest 
rectangle containing the object in an image [70]-[71]. 
Several other morphology features such as circularity, extrema and etc. have been 
calculated and fed to the classifier to compare the results. The highest accuracy achieved 
in this method was 70%. It was observed that primary and secondary tumor cells are not 
that different in morphological aspects. This was expected, as the secondary cells are 
actually just primary cancer cells that break away from the primary tumor where they 
originated and travel via blood or lymph system to another organ to form a secondary tumor 
[72].  
 
4.5.3. Classification- Antibody uptake in grayscale images 
 
In this method, most cases (a case is defined, for example, when the classifier is 
trained based on the information of one patient and then tested with the information of 
another patient) achieved an accuracy of 90 % or higher. This method consisted of the 
normalized intensity related to the amount of protein expressions of different antibodies in 
primary and metastatic tumor cells being fed to the classifier.  
The reason that accuracy in this method -- using normalized intensity of antibody 
uptake in grayscale images -- was much higher than the other methods is that primary and 





but have an observable difference in their amount of protein expression. 
Immunofluorescence images are very sensitive and are therefore very suitable to be used 
to discern and compare how primary and secondary cells are different in the expression of 
their proteins. Even still, when the amount of protein is very low, the cells with low protein 
expression might be hidden behind the cells with high protein expression, in general with 
fluorescent images, the amount of signal in a cell has a linear relationship with the amount 
of protein expression in that cell.  
Table 5 presents the information of the patients whose data has been used in the 
training and testing of the classifier. For instance, PM 80 in the Train column signifies that 
primary and metastatic tumor information of patient 80 has been used to train the classifier. 
Similarly, P116-M8 in the Test column means that the primary information of patient 
number 116 and the metastasis information of patient number 8 have been used to test the 
model. The 4 metrics, which include accuracy, precision, recall and f1 score, have been 
used to evaluate the performance of this classifier. The definition of these metrics and their 
formulas - with abbreviations TP, TN, FP and FN for True Positive, True Negative, False 
Positive and False Negative, respectively - are as follows: [73] 
Accuracy: Number of correct predictions divided by total number of predictions 
Accuracy = TP+TN/TP+FP+FN+TN 
Precision: True positive divided by total number of true positive and false positive 
Precision = TP/TP+FP 






Recall = TP/TP+FN 
F1 score: 2 times precision multiply by recall divided by total number of precision 
and recall 
F1 Score = 2*(Recall * Precision) / (Recall + Precision) 
Though accuracy is very important in the assessment of the performance of a 
classifier, other metrics represent other significant aspects of that classifier as well. For 
instance, high precision implies a low false positive rate. 
The highest accuracy in this method was 96 %. The other metrics confirmed the 
good performance of this classifier. Exceptions to this accuracy occurred for patients such 
as patient 116 for whom the Dapi stained scan of the cells was extremely low in intensity 
for the whole image and for patients for whom the metastasis information was not available 
in the dataset. In instances of the latter, the primary information of the patient had to be 
combined with the metastasis information of another patient in order to contribute to the 
classifier, therefore, the accuracy was not very high. Other than these two exceptions, the 
performance of the designed classifier was high. Nevertheless, this model should be 









Train  Test Accuracy precision       recall   f1-score  
PM 80 PM 105 96 % 0.72 1.00 0.84 
PM 80 P116-M8 65% 0.67       0.96       0.79  
PM 80 P105-ML8 91 % 0.91 1.00 0.95 
PM 105 PM 80 94 % 1.00 0.88 0.94 
PM 105 P116-M8 70% 0.78 0.77 0.78 
PM 105 P80-M70 92 % 1.00 0.88 094 
PM 105 P80-M10 93% 0.98 0.88 0.93 
PM 105 P80-ML8 93% 1.00 0.88 0.94 
Table 5. Metrics for different cases in the classification 
 
 
As we noticed from the results, PCA could cluster the data into two different 
groups. in cases when the primary or metastatic data is both from the same patient, not 
different patients. Most of the variance is explained by PCs 1 and 3 -- the first and the third 
PCs. Using Vector Quantization, though, there is no discernable pattern to cluster the data 
to two or more different groups. 
In supervised methods, we designed two types of classifiers; the first one was based 
on the morphological characteristics of primary versus metastatic tumor cells with the 
highest accuracy of 70%. We noticed that morphological features are not proper choices 
for distinguishing between primary and metastatic tumor cells, as the secondary cells are 
actually just primary cancer cells that break away from the primary tumor where they 
originated and travel via blood or lymph system to another organ to form a secondary 
tumor.  
Our approach for designing the second type of the classifier was based on multiple 
antibodies uptake in the primary versus metastatic tumor cells. For this purpose, we first 
examined the presence of different antibodies in a cell and later the amount of protein 
expressions in different antibodies. We achieved the accuracy of 90% and higher in this 





terms of morphology and antibody uptake, but have an observable difference in their 
amount of protein expression. Also, , in general with fluorescent images, the amount of 
signal in a cell has a linear relationship with the amount of protein expression in that cell 
and this makes this kind of image a good choice for detecting the amount of a specific 








































Summary, Conclusions and, Future Work 
 
The high mortality rate of pancreatic cancer and its poor response to common 
cancer treatments such as radiotherapy, immunotherapy, and chemotherapy have fueled 
research to develop novel therapeutic approaches for the diagnosis, treatment, and possibly 
cure of this highly lethal disease. 
 
Tumor associated biomarkers are currently being intensively studied and have 
shown encouraging results for the management of pancreatic cancers. However, metastasis 
which is responsible for about 90 % of cancer deaths, is poorly understood. Understanding 
the biology and the dynamic of metastasis is crucial in the discovery and development of 
innovative therapies for this challenging cancer. Comparison of the absence or presence of 
validated biomarkers in primary versus secondary tumor sites can bring an insight into how 
the two tumors are different despite being originated from the same organ, and this can in 
turn help with revising the available or developing new treatment methods.  
 
In this project, our ultimate goal was to design a classifier to classify pancreatic 
tumor cells into two categories; primary or metastatic. Most of the literature deals with the 
differences between normal cells and tumor cells and the classifiers are designed based on 
these differences. We aimed to examine the differences between primary versus metastatic 
tumor cells and investigate if the classifier could classify these cells based on two different 





For this purpose, after registering consecutive images of the same tissue slide 
together, first we investigated whether using unsupervised clustering methods such as 
Vector Quantization (VQ) and Principal Component Analysis (PCA) we could cluster 
primary metastatic cells into two different groups.  
 
We noticed from the results, in cases when the data is both primary or metastatic 
but from different patients, PCA could not cluster the data into two different groups. 
However, when the dataset is primary-metastasis data from one patient, PCA has clustered 
the data to almost two different clusters. Nevertheless, the results overlap in some cases 
and this makes them not very reliable. Most of the variance is explained by PCs 1 and 3 -- 
the first and the third PCs.   
In Vector Quantization, though, there is no specific pattern to distinguish between 
two or more different groups. 
In the classification methods, we designed two types of classifiers; the first one was 
based on the morphological characteristics of primary versus metastatic tumor cells. In this 
method, features such as area, perimeter, solidity, eccentricity etc. were analyzed to 
examine if primary and metastatic tumor cells are morphologically different.  
The highest accuracy achieved in this method was 70%. It was observed that 
primary and secondary tumor cells are not that different in morphological aspects. This 
was expected, as the secondary cells are actually just primary cancer cells that break away 
from the primary tumor where they originated and travel via blood or lymph system to 





The second type of the classifier was based on antibody uptake in the primary 
versus metastatic tumor cells. In this method, we first used the presence versus the absence 
of the antibodies in the binary images of our dataset as features to be fed to the classifier 
and later the normalized intensity related to the amount of protein expressions of different 
antibodies in primary and metastatic tumor cells.  
In the first method, the highest accuracy reached was 82%, however,  in the second 
method, most cases (a case is defined, for example, when the classifier is trained based on 
the information of one patient and then tested with the information of another patient) 
achieved an accuracy of 90 % or higher. This method consisted of the normalized intensity 
related to the amount of protein expressions of different antibodies in primary and 
metastatic tumor cells being fed to the classifier.  
The reason that accuracy in this method -- using the normalized intensity of 
antibody uptake in grayscale images -- was much higher than the other methods is that 
primary and metastatic tumor cells are mostly the same in terms of morphology and 
antibody uptake, but have an observable difference in their amount of protein expression. 
Immunofluorescence whole slide images are highly sensitive and are therefore very 
suitable to be used to discern and compare how primary and secondary cells are different 
in the expression of their proteins. Even still, when the amount of protein is very low, the 
cells with low protein expression might be hidden behind the cells with high protein 
expression, in general with fluorescent images, the amount of signal in a cell has a linear 





Since the classifier is first trained based on the binary and later the grayscale images 
of the antibodies of primary and metastatic pancreatic cancer tissues, the next step in this 
work could be to investigate how the expression of a particular antibody or different panels 
of antibodies are quantitatively different in primary versus metastatic tumor cells. Also, 
since our dataset is considered a small dataset, further research will include examining the 
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